8,681 Shares in AtriCure, Inc. $ATRC Purchased by Campbell & CO Investment Adviser LLC

Campbell & CO Investment Adviser LLC purchased a new stake in AtriCure, Inc. (NASDAQ:ATRC) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 8,681 shares of the medical device company’s stock, valued at approximately $284,000.

Other hedge funds also recently made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of AtriCure by 18.2% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 264,344 shares of the medical device company’s stock valued at $8,663,000 after buying an additional 40,775 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in AtriCure by 1.0% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 755,537 shares of the medical device company’s stock worth $24,759,000 after purchasing an additional 7,731 shares in the last quarter. Nicholas Company Inc. raised its holdings in AtriCure by 8.5% during the 2nd quarter. Nicholas Company Inc. now owns 192,635 shares of the medical device company’s stock worth $6,313,000 after buying an additional 15,135 shares during the period. Teacher Retirement System of Texas boosted its holdings in shares of AtriCure by 5.4% in the second quarter. Teacher Retirement System of Texas now owns 7,512 shares of the medical device company’s stock worth $246,000 after buying an additional 385 shares during the period. Finally, Riverwater Partners LLC purchased a new position in shares of AtriCure in the second quarter worth approximately $1,103,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

Insider Buying and Selling at AtriCure

In other news, Director Sven Wehrwein sold 5,000 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $37.00, for a total transaction of $185,000.00. Following the transaction, the director owned 34,374 shares of the company’s stock, valued at approximately $1,271,838. This represents a 12.70% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Justin J. Noznesky sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $36.30, for a total value of $108,900.00. Following the completion of the sale, the insider owned 83,964 shares of the company’s stock, valued at approximately $3,047,893.20. This trade represents a 3.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 3.50% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of AtriCure in a research report on Wednesday, October 8th. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research report on Thursday, October 30th. BTIG Research set a $54.00 price objective on AtriCure in a research report on Wednesday, July 30th. Needham & Company LLC increased their price target on shares of AtriCure from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Wednesday, July 30th. Finally, Wall Street Zen upgraded shares of AtriCure from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, AtriCure has a consensus rating of “Moderate Buy” and a consensus price target of $52.22.

AtriCure Price Performance

Shares of ATRC opened at $33.12 on Tuesday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.83 and a current ratio of 3.94. The firm has a market cap of $1.65 billion, a PE ratio of -54.29 and a beta of 1.56. The firm’s 50 day moving average price is $35.15 and its 200 day moving average price is $33.99. AtriCure, Inc. has a twelve month low of $28.29 and a twelve month high of $43.11.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Wednesday, October 29th. The medical device company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.10. The company had revenue of $134.27 million during the quarter, compared to the consensus estimate of $131.25 million. AtriCure had a negative net margin of 5.55% and a negative return on equity of 2.56%. The company’s revenue for the quarter was up 15.8% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.17) earnings per share. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. As a group, research analysts expect that AtriCure, Inc. will post -0.6 EPS for the current fiscal year.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.